References

References

 

    1. Relling, M.V. and W.E. Evans, Pharmacogenomics in the clinic. Nature, 2015. 526: 343-50.
    2. Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
    3. Hicks J, Swen J, Thorn C, Sangkuhl K, Kharasch E, Ellingrod V et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013;93(5):402-408.
    4. Crews K, Gaedigk A, Dunnenberger H, Leeder J, Klein T, Caudle K et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clin Pharmacol Ther. 2014;95(4):376-382.
    5. Crews K, Gaedigk A, Dunnenberger H, Klein T, Shen D, Callaghan J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clin Pharmacol Ther. 2011;91(2):321-326.
    6. Shah R, Smith R. Addressing phenoconversion: the Achilles’ heel of personalized medicine. British Journal of Clinical Pharmacology. 2015;79(2):222-240.
    7. Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clin Pharmacol Ther. 2013;94(3):317-323.
    8. Hicks J, Bishop J, Sangkuhl K, Müller D, Ji Y, Leckband S et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology & Therapeutics. 2015;98(2):127-134.
    9. Schroth, W et al. JAMA 302(13):1429-1436 (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with Tamoxifen.
    10. Walko, CM and Mcleod, H. Pharmacogenomics 13(6): 691-697 (2012). Use of CYP2D6 genotyping in practice: Tamoxifen dose adjustment.
    11. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Eng J Med. 2008 Aug 21;359(8):789-99.
    12. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The Clinical Pharmacogenetics Implementation Consortium Guidelines for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. Online publication 9 July 2014. doi:10.1038/clpt.2014.125

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close